Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Inoviv Secures Investment to Enhance Quantitative Proteomics
Details : The net proceeds will be used to accelerate company's drug development pipelines, including HER-096, developed from neurotrophic factor CDNF, a groundbreaking approach to Parkinson's disease.
Product Name : HER-096
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 30, 2024